Dr. Xing Lv 吕星
Chief Physician
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical diagnosis and comprehensive treatment of nasopharyngeal carcinoma, including radiotherapy, chemotherapy, and immunotherapy.
Chief Physician and doctoral supervisor at Sun Yat-sen University Cancer Center. Research focuses on individualized comprehensive treatment for nasopharyngeal carcinoma. Dr. Lv has led or participated in multiple prospective randomized controlled clinical trials and national or provincial research projects. Over 30 SCI papers were published as first or corresponding author in journals such as The Lancet Oncology and JNCI.
Professional roles
- Youth Committee Member, Radiotherapy Professional Committee, Chinese Medical Doctor Association
- Youth Committee Member, Tumor Microenvironment Professional Committee, China Anti-Cancer Association
- Vice Chair, Youth Committee of Radiotherapy Professional Committee, Guangdong Anti-Cancer Association
- Standing Committee Member, Otolaryngology-Head and Neck Surgery Management Committee, Guangdong Medical Industry Association
Name order: in Chinese the family name comes first (Lv Xing). Papers usually list the name as Xing Lv or Lv X.
Selected publications
81 papers on PubMed matched by name and affiliation; 24 as first or senior author since 2016. Most recent first- or senior-author papers:
- Pharmacol Rep, 2026 (senior author): Association between elemental concentrations and chemotherapy-related acute adverse events in patients with nasopharyngeal carcinoma. PubMed 42207470
- Nat Commun, 2026 (senior author): Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial. PubMed 41667463
- Int J Cancer, 2025 (senior author): Optimal therapeutic strategies for hepatic metachronous oligometastatic nasopharyngeal carcinoma: Insights from a retrospective study. PubMed 39187950
- Radiother Oncol, 2024 (senior author): Anxiety and depression in nasopharyngeal carcinoma patients and network analysis to identify central symptoms: A cross-sectional study from a high-incidence area. PubMed 38735537
- Lancet Psychiatry, 2023 (senior author): Improving mental health care among patients with cancer in China. PubMed 37863521
- Cancer Med, 2023 (senior author): Incidence, consequences, and predictors of serious chemotherapy-induced thrombocytopenia in nasopharyngeal carcinoma. PubMed 37212462
- Lipids Health Dis, 2023 (senior author): Widely targeted quantitative lipidomics and prognostic model reveal plasma lipid predictors for nasopharyngeal carcinoma. PubMed 37365637
- J Cancer Res Clin Oncol, 2023 (senior author): Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis. PubMed 36289067
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion